Tata India Pharma & Healthcare Fund is a Thematic fund run by Tata Mutual Fund. On 30-09-2026, it managed ₹1,511 Cr of investors' money. In the 3 years to 30-10-2026, its Direct plan returned 19.3% a year and its Regular plan returned 17.6% a year. Its benchmark, BSE Healthcare TRI, returned 23.0% a year over the same 3 years.
NAV (Direct plan)
₹37.77
▲ 0.60% · 30-10-2026
NAV (Regular plan)
₹31.88
▲ 0.60% · 30-10-2026
Expense ratio
1.10%Direct2.42%Regular
1.10%
A year
Riskometer
Very High
Set by the fund house
3 year return
19.3%Direct17.6%Regular
19.3%
A year
Tata India Pharma & Healthcare Fund NAV Today
NAV on 30-10-2026: Direct Plan Growth ₹37.77 (up 0.60% that day); Regular Plan Growth ₹31.88 (up 0.60% that day).
This fund (Direct plan)
₹37.7655
Tata India Pharma & Healthcare Fund Returns vs BSE Healthcare TRI
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
Trailing returns
Period
1M
3M
6M
1Y
3Y
5Y
10Y
This fund (Direct)
−1.40%
−5.00%
+6.91%
+4.28%
+19.28%
+14.93%
+14.64%
This fund (Regular)
−1.51%
−5.33%
+6.17%
+2.82%
+17.55%
+13.24%
+12.88%
BSE Healthcare TRI
+0.24%
−0.99%
+12.80%
+12.37%
+23.01%
+15.61%
+12.48%
Thematic average
−2.09%
−4.52%
+0.86%
−1.22%
+13.76%
+11.62%
+13.76%
Best in Thematic
+11.54%
+11.27%
+22.16%
+75.71%
+54.78%
+21.14%
+19.31%
Worst in Thematic
−16.05%
−11.74%
−13.97%
−22.44%
−4.46%
+3.65%
+7.72%
Rank in Thematic
84/235
104/232
50/232
53/215
25/133
25/96
24/63
Category rows compare the Direct plans of 235 Thematic funds. Rank 1 is the highest return.
Tata India Pharma & Healthcare Fund Year-wise Returns
Return of each calendar year
Year
Direct
Regular
BSE Healthcare TRI
2026to date
+6.77%
+5.53%
+15.08%
2025
−3.47%
−4.92%
−2.72%
2024
+42.48%
+40.40%
+44.30%
2023
+38.59%
+36.58%
+37.97%
2022
−6.64%
−8.04%
−11.50%
2021
+20.88%
+19.07%
+21.54%
Tata India Pharma & Healthcare Fund Rolling Returns
The return of every holding period in the fund's history, not only the one that ends today
Rolling returns
Each point is the yearly return of one 3-year holding period, plotted on the day it ended. There are 1,930 periods, one for each trading day from 31-12-2018 to 30-10-2026.
−10%0%10%20%30%
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Aug 2016 to Aug 2019Dec 2017 to Dec 2020Apr 2019 to Apr 2022Aug 2020 to Aug 2023Dec 2021 to Dec 2024Mar 2023 to Mar 2026
Tata India Pharma & Healthcare Fund (Direct)BSE Healthcare TRI
9%
17%
Below 0%
6%
2%
0-5%
3%
2%
5-10%
3%
14%
10-15%
21%
23%
15-20%
38%
34%
20-25%
20%
9%
Above 25%
Every holding period at a glance
Period
Periods
Median
Lowest
Highest
With a loss
Benchmark median
Beat benchmark
1 year
2,423
8.8%
−17.3%
76.3%
29%
7.6%
66%
2 years
2,175
14.4%
−6.8%
47.1%
10%
12.4%
73%
3 years
1,930
21.2%
−3.4%
30.5%
9%
19.0%
83%
5 years
1,438
16.7%
9.3%
31.6%
0%
14.4%
96%
7 years
943
20.3%
8.1%
23.4%
0%
17.4%
97%
10 years
206
14.5%
12.6%
15.3%
0%
12.4%
100%
Every SIP holding period at a glance
Period
Periods
Median
Lowest
Highest
With a loss
Benchmark median
Beat benchmark
1 year
119
7.9%
−17.0%
77.5%
28%
5.5%
62%
2 years
107
14.0%
−7.7%
52.0%
11%
13.9%
67%
3 years
95
18.2%
−0.3%
39.8%
3%
19.0%
76%
5 years
71
20.4%
13.6%
30.6%
0%
19.0%
87%
7 years
47
20.8%
12.3%
27.1%
0%
19.4%
89%
Lumpsum: the yearly rate (CAGR) from the NAV on a period's first day to the NAV on its last. SIP: the XIRR of the monthly instalments and their value on the last day. "With a loss" counts the periods that ended below the money put in. "Beat benchmark" counts the periods in which the fund did better than BSE Healthcare TRI over the same days. Past returns do not promise future returns.
Tata India Pharma & Healthcare Fund Risk
How much it swings, and the falls an investor had to sit through
Risk and return
Measure
Tata India Pharma & Healthcare Fund (Direct)This fund
BSE Healthcare TRI
Return (CAGR)
+4.28%
+12.37%
Standard deviation
11.99%
13.56%
Sharpe ratio
-0.08
0.53
Sortino ratio
-0.11
0.77
Maximum drawdown
−11.0%
(23-10-2026)
−9.9%
(23-10-2026)
Beta
0.82
1.00
Alpha
−6.83%
0.00%
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
Measure
Tata India Pharma & Healthcare Fund (Direct)This fund
BSE Healthcare TRI
Return (CAGR)
+19.28%
+23.01%
Standard deviation
13.21%
14.12%
Sharpe ratio
1.00
1.20
Sortino ratio
1.43
1.71
Maximum drawdown
−16.8%
(28-02-2025)
−16.2%
(28-02-2025)
Beta
0.89
1.00
Alpha
−1.91%
0.00%
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
Measure
Tata India Pharma & Healthcare Fund (Direct)This fund
BSE Healthcare TRI
Return (CAGR)
+14.93%
+15.61%
Standard deviation
12.92%
13.97%
Sharpe ratio
0.71
0.70
Sortino ratio
1.01
1.00
Maximum drawdown
−16.8%
(28-02-2025)
−19.6%
(17-06-2022)
Beta
0.89
1.00
Alpha
+0.41%
0.00%
From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
Measure
Tata India Pharma & Healthcare Fund (Direct)This fund
BSE Healthcare TRI
Return (CAGR)
+14.64%
+12.48%
Standard deviation
15.17%
16.56%
Sharpe ratio
0.61
0.43
Sortino ratio
0.88
0.60
Maximum drawdown
−18.5%
(23-03-2020)
−31.6%
(23-03-2020)
Beta
0.88
1.00
Alpha
+3.05%
0.00%
From daily NAVs, 28-10-2016 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
Measure
Tata India Pharma & Healthcare Fund (Direct)This fund
BSE Healthcare TRI
Return (CAGR)
+13.01%
+11.22%
Standard deviation
15.08%
16.52%
Sharpe ratio
0.50
0.35
Sortino ratio
0.72
0.49
Maximum drawdown
−19.8%
(21-08-2017)
−33.2%
(23-03-2020)
Beta
0.87
1.00
Alpha
+2.53%
0.00%
From daily NAVs, 29-12-2015 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta: 1 moves with the benchmark, below 1 moves less. Alpha: return beyond what its beta explains, a year.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
−40%−30%−20%−10%0%
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
201620182020202220242026
Tata India Pharma & Healthcare Fund (Direct)BSE Healthcare TRI
Worst fall
High before it
Bottom
Back at the high
Time to climb back
Below its high today
Tata India Pharma & Healthcare Fund (Direct)
−19.8%
01-02-2016
21-08-2017
31-08-2018
12 months
−6.0%
BSE Healthcare TRI
−33.2%
29-12-2015
23-03-2020
22-06-2020
3 months
−3.8%
From the Direct plan's daily NAV since 29-12-2015, adjusted for unit splits, and BSE Healthcare TRI over the same days. "Time to climb back" runs from the bottom to the first day back at the old high.
Tata India Pharma & Healthcare Fund vs Other Thematic Funds
The five Thematic funds with the best three year return, and this fund. Direct plans.
AUM is each fund's size at the end of its last reported month, from its own portfolio file. We calculate the risk ratios from daily NAVs over the last three years. The risk-free return is what NSE's overnight rate index earned over the same years. Alpha and beta compare each fund with its own benchmark's TRI. "--" means we have no figure: for alpha and beta, no daily series for that benchmark.
Tata India Pharma & Healthcare Fund Expense Ratio and Costs
What each plan charges a year, in force from 21-10-2026
Plan
Base expense ratio
Brokerage
Transaction costs
Levies and GST
Total expense ratio
Thematic median
Cost rank (1 = cheapest)
Direct
0.64%
0.11%
0.01%
0.34%
1.10%
1.18%
94/235
Regular
1.82%
0.11%
0.01%
0.48%
2.42%
2.41%
120/235
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, the cost of executing trades, and statutory levies with GST. From AMFI's expense ratio file. Cost rank: where this plan comes when the Thematic funds' plans of the same type are sorted from the lowest total expense ratio to the highest.
Direct vs Regular: what the gap cost
Both plans own the same portfolio, so the difference in what they earned is the Regular plan's extra cost, taken out of its NAV.
Over the last
Regular
Direct
Direct earned more by
₹1 lakh became (Regular)
₹1 lakh became (Direct)
1 year
2.82%
4.28%
1.46%
₹1,02,820
₹1,04,280
3 years
17.55%
19.28%
1.73% a year
₹1,62,431
₹1,69,708
5 years
13.24%
14.93%
1.69% a year
₹1,86,208
₹2,00,524
10 years
12.88%
14.64%
1.76% a year
₹3,35,869
₹3,92,068
Returns over more than 1 year are a rate a year (CAGR). ₹1 lakh invested once at the start of each period, valued on the last NAV.
Tata India Pharma & Healthcare Fund SIP Calculator
What a one-time or monthly investment in this fund would be worth today, from its own NAV history
Growth of an investment
Step up each year
PeriodFor
₹10,000 on the first trading day of every month, from 29-12-2015 to 30-10-2026: 131 instalments, ₹13,10,000 in all.
Investment
Invested
Value now
Gain
Return a year
Direct planTata India Pharma & Healthcare Fund (Direct)
₹13,10,000
₹34,72,173
₹21,62,173
16.9%
Regular planTata India Pharma & Healthcare Fund (Regular)
Direct planTata India Pharma & Healthcare Fund (Direct)Regular planTata India Pharma & Healthcare Fund (Regular)BSE Healthcare TRICategory averageCategory average, 235 Thematic fundsAmount invested
From each plan's published NAV (Growth option), the benchmark's TRI and the category average, over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Tata India Pharma & Healthcare Fund Asset Allocation
Asset allocation as on 30-09-2026
What the fund holds
99.7%Equity
Asset
Fund
Category
Equity
99.7%
94.5%
Cash and others
0.3%
4.0%
Market cap of stocks
Market cap
Fund
Category
Large Cap
26.0%
45.7%
Mid Cap
33.9%
19.6%
Small Cap
37.0%
24.1%
Not on AMFI's list
2.9%
2.3%
Share of the whole fund. Category: the average of the Thematic funds that hold stocks. Groups follow AMFI's latest list, as SEBI defines them: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Tata India Pharma & Healthcare Fund Sector Allocation
Sector allocation of the fund's stocks as on 30-09-2026
Largest sectors
Pharmaceuticals & Biotechnology60.6%
Healthcare Services27.8%
Fertilizers & Agrochemicals6.9%
Chemicals & Petrochemicals2.6%
Personal Products1.2%
Healthcare Equipment & Supplies0.5%
Sector changes
Sector
July 2026
August 2026
September 2026
Change
Pharmaceuticals & Biotechnology
60.3%
58.3%
60.6%
+0.3%
Healthcare Services
31.9%
34.1%
27.8%
−4.1%
Fertilizers & Agrochemicals
4.8%
5.5%
6.9%
+2.0%
Chemicals & Petrochemicals
1.0%
--
2.6%
+1.6%
Personal Products
1.1%
1.1%
1.2%
0.0%
Each sector's share of the fund at the end of each month. The five largest sectors of September 2026. Change: from July 2026 to September 2026, in % of the fund.
Tata India Pharma & Healthcare Fund Portfolio Holdings
As on 30-09-2026 · 42 holdings · from the fund house's monthly portfolio
Holdings
Sector
Weight%
Holdings trend
1M change
SUN PHARMACEUTICAL INDUSTRIES LTD
Pharmaceuticals & Biotechnology
7.99%
0.0%
ABBOTT INDIA LTD
Pharmaceuticals & Biotechnology
5.94%
+0.5%
HEALTHCARE GLOBAL ENTERPRISES LTD
Healthcare Services
5.92%
0.0%
DIVI LABORATORIES LTD
Pharmaceuticals & Biotechnology
5.68%
−1.2%
DR REDDYS LABORATORIES LTD
Pharmaceuticals & Biotechnology
4.65%
0.0%
APOLLO HOSPITALS ENTERPRISE LTD
Healthcare Services
4.36%
+6.2%
RAINBOW CHILDRENS MEDICARE LTD
Healthcare Services
4.30%
0.0%
CIPLA LTD
Pharmaceuticals & Biotechnology
4.22%
0.0%
TORRENT PHARMACEUTICALS LTD
Pharmaceuticals & Biotechnology
3.76%
+3068.5%
MAX HEALTHCARE INSTITUTE LTD
Healthcare Services
3.71%
+5.6%
LUPIN LTD
Pharmaceuticals & Biotechnology
3.14%
0.0%
BAYER CROPSCIENCE LTD
Fertilizers & Agrochemicals
2.96%
+3.7%
SYNGENE INTERNATIONAL LTD
Healthcare Services
2.85%
0.0%
PROCTER & GAMBLE HEALTH LTD
Pharmaceuticals & Biotechnology
2.75%
+9.7%
SAI LIFE SCIENCES LTD
Pharmaceuticals & Biotechnology
2.60%
0.0%
PI INDUSTRIES LTD
Fertilizers & Agrochemicals
2.59%
+168.8%
ANTHEM BIOSCIENCES LTD
Pharmaceuticals & Biotechnology
2.57%
+21.0%
PFIZER LTD
Pharmaceuticals & Biotechnology
2.50%
0.0%
ALKEM LABORATORIES LTD
Pharmaceuticals & Biotechnology
2.36%
0.0%
FDC LTD
Pharmaceuticals & Biotechnology
2.24%
+2.2%
FORTIS HEALTHCARE LTD
Healthcare Services
1.95%
−32.7%
ACUTAAS CHEMICALS LTD
Pharmaceuticals & Biotechnology
1.95%
+22.3%
DR. LAL PATH LABS LTD
Healthcare Services
1.76%
0.0%
ASTER DM QUALITY CARE LTD
Healthcare Services
1.67%
+9.9%
AJANTA PHARMA LTD
Pharmaceuticals & Biotechnology
1.63%
0.0%
NATCO PHARMA LTD
Pharmaceuticals & Biotechnology
1.51%
New
SUMITOMO CHEMICAL INDIA LTD
Fertilizers & Agrochemicals
1.38%
0.0%
GILLETTE INDIA LTD
Personal Products
1.23%
+14.2%
NAVIN FLUORINE INTERNATIONAL LTD
Chemicals & Petrochemicals
1.18%
New
IPCA LABORATORIES LTD
Pharmaceuticals & Biotechnology
0.91%
0.0%
PRASOL CHEMICALS LTD
Chemicals & Petrochemicals
0.88%
New
SYMBIOTEC PHARMALAB LTD
Pharmaceuticals & Biotechnology
0.87%
+10.9%
MANKIND PHARMA LTD
Pharmaceuticals & Biotechnology
0.77%
−75.5%
GLAXOSMITHKLINE PHARMACEUTICALS LTD
Pharmaceuticals & Biotechnology
0.76%
−70.2%
BIOCON LTD
Pharmaceuticals & Biotechnology
0.69%
−25.7%
DR. AGARWALS HEALTH CARE LTD
Healthcare Services
0.68%
0.0%
MANIPAL HEALTH ENTERPRISES LTD
Healthcare Services
0.59%
−50.0%
ZIM LABORATORIES LTD
Pharmaceuticals & Biotechnology
0.58%
0.0%
SANOFI CONSUMER HEALTHCARE INDIA LTD
Pharmaceuticals & Biotechnology
0.57%
+15.0%
MOLBIO DIAGNOSTICS LTD
Healthcare Equipment & Supplies
0.54%
−50.7%
GUJARAT FLUOROCHEMICALS LTD
Chemicals & Petrochemicals
0.53%
New
JUBILANT PHARMOVA LTD
Pharmaceuticals & Biotechnology
0.00%
−99.9%
Tata India Pharma & Healthcare Fund Stocks Bought and Sold
All changes are between August 2026 and September 2026
More
Stocks bought and sold in September 2026
ABBOTT INDIA LTD
↑Added
+0.5%
5.94%
DIVI LABORATORIES LTD
↓Reduced
−1.2%
5.68%
APOLLO HOSPITALS ENTERPRISE LTD
↑Added
+6.2%
4.36%
MAX HEALTHCARE INSTITUTE LTD
↑Added
+5.6%
3.71%
TORRENT PHARMACEUTICALS LTD
↑Added
+3068.5%
3.76%
FORTIS HEALTHCARE LTD
↓Reduced
−32.7%
1.95%
BAYER CROPSCIENCE LTD
↑Added
+3.7%
2.96%
MANKIND PHARMA LTD
↓Reduced
−75.5%
0.77%
PROCTER & GAMBLE HEALTH LTD
↑Added
+9.7%
2.75%
GLAXOSMITHKLINE PHARMACEUTICALS LTD
↓Reduced
−70.2%
0.76%
PI INDUSTRIES LTD
↑Added
+168.8%
2.59%
ANTHEM BIOSCIENCES LTD
↑Added
+21.0%
2.57%
FDC LTD
↑Added
+2.2%
2.24%
ACUTAAS CHEMICALS LTD
↑Added
+22.3%
1.95%
GLOBAL HEALTH LTD
↓Sold out
−100%
was 1.68%
ASTER DM QUALITY CARE LTD
↑Added
+9.9%
1.67%
NATCO PHARMA LTD
↑New
New
1.51%
MANIPAL HEALTH ENTERPRISES LTD
↓Reduced
−50.0%
0.59%
GILLETTE INDIA LTD
↑Added
+14.2%
1.23%
NAVIN FLUORINE INTERNATIONAL LTD
↑New
New
1.18%
METROPOLIS HEALTHCARE LTD
↓Sold out
−100%
was 1.11%
BIOCON LTD
↓Reduced
−25.7%
0.69%
PRASOL CHEMICALS LTD
↑New
New
0.88%
MOLBIO DIAGNOSTICS LTD
↓Reduced
−50.7%
0.54%
SYMBIOTEC PHARMALAB LTD
↑Added
+10.9%
0.87%
SANOFI CONSUMER HEALTHCARE INDIA LTD
↑Added
+15.0%
0.57%
GUJARAT FLUOROCHEMICALS LTD
↑New
New
0.53%
HDFC LIFE INSURANCE CO. LTD
↓Sold out
−100%
was 0.50%
JUBILANT PHARMOVA LTD
↓Reduced
−99.9%
0.00%
No stocks in this group for September 2026.
A change is counted by the number of shares the fund holds, not by price. A stock can become a smaller part of the fund in a month when the fund bought more of it, if its price fell. Debt papers are left out.
Overlap: for each holding both funds own, the smaller of its two weights, added up. 40% means 40% of each fund's money sits in positions the other also holds. From each fund's latest monthly portfolio, matched by ISIN. Cash and hedged positions are left out. Funds that overlap under 10% are not listed. A high overlap does not make two funds the same: their costs, lock-in and category can differ.
Tata India Pharma & Healthcare Fund Overview
Fund facts from the scheme summary document, as on 16-10-2026
Expense ratio (Direct)
1.10%
Expense ratio (Regular)
2.42%
Category
Thematic
Risk
Very High
Benchmark
BSE Healthcare TRI
Launch date
28-12-2015
Minimum investment
₹5,000
Minimum additional investment
₹1,000
AUM
₹1,511.49 Cr (30-09-2026)
Lock in
None
Scheme code (Direct)
135810
ISIN (Direct)
INF277K019A3
Scheme code (Regular)
135812
ISIN (Regular)
INF277K016A9
NAV history
From 29-12-2015, 10.8 years
Exit load
0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.
Tax on Tata India Pharma & Healthcare Fund returns
Tata India Pharma & Healthcare Fund is taxed as an equity fund: 65% or more of it is in Indian stocks.
Units sold within 1 year: the gain is taxed at 20%.
Units held longer: gains above ₹1.25 lakh in a financial year, across all your equity funds and shares, are taxed at 12.5%.
IDCW (dividend) payouts are added to your income and taxed at your slab rate.
A stamp duty of 0.005% is deducted when you invest.
Rules in force from 23-07-2024 (Finance Act 2024). Tax depends on your own income; this is general information, not tax advice.
All plans and options
Plan
Option
NAV
As on
direct
Payout Income Distribution Cum Capital Withdrawal
₹36.538
30-10-2026
direct
Reinvestment Income Distribution Cum Capital Withdrawal
₹36.538
30-10-2026
direct
Growth
₹37.7655
30-10-2026
regular
Payout Income Distribution Cum Capital Withdrawal
₹30.6604
30-10-2026
regular
Reinvestment Income Distribution Cum Capital Withdrawal
₹30.6604
30-10-2026
regular
Growth
₹31.8801
30-10-2026
About Tata India Pharma & Healthcare Fund
Tata India Pharma & Healthcare Fund is a mutual fund from Tata Mutual Fund. Its category is Thematic. It was launched on 28-12-2015. Its benchmark is BSE Healthcare TRI. At the end of September 2026 it held 42 securities.
Fund Manager
Rajat Srivastava
Fund manager of Tata India Pharma & Healthcare Fund, since 16-09-2024
Frequently Asked Questions for Tata India Pharma & Healthcare Fund
What is the current NAV of Tata India Pharma & Healthcare Fund?
The Direct plan NAV is ₹37.7655. The Regular plan NAV is ₹31.8801, as on 30-10-2026.
What are the returns of Tata India Pharma & Healthcare Fund?
The Direct plan returned +4.28% in 1 year, +19.28% a year over 3 years, +14.93% a year over 5 years. The Regular plan returned +2.82% in 1 year, +17.55% a year over 3 years, +13.24% a year over 5 years. These figures are as on 30-10-2026.
What is the expense ratio of Tata India Pharma & Healthcare Fund?
The Direct plan charges 1.10% a year. The Regular plan charges 2.42% a year. This is the figure the fund house reported to AMFI, in force from 21-10-2026.
What is the AUM of Tata India Pharma & Healthcare Fund?
Tata India Pharma & Healthcare Fund managed ₹1,511.49 Cr on 30-09-2026, as its fund house reported in its monthly portfolio.
What are the top holdings of Tata India Pharma & Healthcare Fund?
At the end of September 2026 the largest holdings were SUNPHARMA (7.99%), ABBOTINDIA (5.94%), HCG (5.92%), DIVISLAB (5.68%), DRREDDY (4.65%). The fund held 42 securities in all.
What did Tata India Pharma & Healthcare Fund buy and sell in September 2026?
It bought 4 new stocks: NAVIN FLUORINE INTERNATIONAL LTD, GUJARAT FLUOROCHEMICALS LTD, PRASOL CHEMICALS LTD, NATCO PHARMA LTD. It sold out of 3: METROPOLIS HEALTHCARE LTD, GLOBAL HEALTH LTD, HDFC LIFE INSURANCE CO. LTD. It added shares in 14. It reduced 8.
How do I invest in Tata India Pharma & Healthcare Fund?
Through Tata Mutual Fund's website or app, a mutual fund distributor, or an investment platform. Choose the Direct plan to pay no distributor commission, or the Regular plan to invest through a distributor. The first investment is at least ₹5,000. You can invest once or through a monthly SIP.
Who is the fund manager of Tata India Pharma & Healthcare Fund?
Rajat Srivastava (since 16-09-2024).
Sources: NAV and expense ratio from AMFI. Holdings from the fund house's monthly portfolio statement. Fund facts from its scheme summary document, as on 16-10-2026.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.
Track Tata India Pharma & Healthcare Fund in WealthGamma
Add this fund once. WealthGamma updates its value every day and shows it next to your stocks, gold, deposits and loans.